The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (14): 2027-2030.doi: 10.3969/j.issn.1006-5725.2024.14.021
• Reviews • Previous Articles Next Articles
Kexin XI1(),Yuqi ZHAO1,2,Xiaoting XIE1,Yuntao LU2,Hongying FAN1,Xiaoyan. HE2(
)
Received:
2023-08-22
Online:
2024-07-25
Published:
2024-07-15
Contact:
Kexin XI,Xiaoyan. HE
E-mail:1094794855@qq.com
CLC Number:
Kexin XI,Yuqi ZHAO,Xiaoting XIE,Yuntao LU,Hongying FAN,Xiaoyan. HE. Research progress on the regulation of intestinal flora on glioma[J]. The Journal of Practical Medicine, 2024, 40(14): 2027-2030.
1 |
XU S, TANG L, LI X, et al. Immunotherapy for glioma:current management and future application[J]. Cancer Lett, 2020, 476:1-12. doi:10.1016/j.canlet.2020.02.002
doi: 10.1016/j.canlet.2020.02.002 |
2 |
GUSYATINER O, HEGI M E. Glioma epigenetics: From subclassification to novel treatment options[J]. Semin Cancer Biol, 2018, 51:50-58. doi:10.1016/j.semcancer.2017.11.010
doi: 10.1016/j.semcancer.2017.11.010 |
3 |
ESLAHI M, DANA P M, ASEMI Z, et al. The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment[J]. Int J Biol Macromol, 2021,168:124-129. doi:10.1016/j.ijbiomac.2020.11.180
doi: 10.1016/j.ijbiomac.2020.11.180 |
4 |
姜海啸,曾巍,张恒柱,等. 肠道菌群及其代谢产物在胶质瘤中的调控机制研究进展[J]. 肿瘤预防与治疗, 2022,35(4):388-392. doi:10.3969/j.issn.1674-0904.2022.04.013
doi: 10.3969/j.issn.1674-0904.2022.04.013 |
5 |
MA P J, WANG M M, WANG Y. Gut microbiota: A new insight into lung diseases[J]. Biomed Pharmacother, 2022,155:113810. doi:10.1016/j.biopha.2022.113810
doi: 10.1016/j.biopha.2022.113810 |
6 |
BIDELL M R, HOBBS A L V, LODISE T P. Gut microbiome health and dysbiosis: A clinical primer[J]. Pharmacotherapy, 2022, 42(11):849-857. doi:10.1002/phar.2731
doi: 10.1002/phar.2731 |
7 |
QUAGLIO A E V, GRILLO T G, DE OLIVEIRA E C S, et al. Gut microbiota, inflammatory bowel disease and colorectal cancer[J]. World J Gastroenterol, 2022, 28(30):4053-4060. doi:10.3748/wjg.v28.i30.4053
doi: 10.3748/wjg.v28.i30.4053 |
8 |
LONG Y, TANG L, ZHOU Y, et al. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study[J]. BMC Med, 2023,21(1):66. doi:10.1186/s12916-023-02761-6
doi: 10.1186/s12916-023-02761-6 |
9 |
MANOS J. The human microbiome in disease and pathology[J]. APMIS, 2022,130(12):690-705. doi:10.1111/apm.13225
doi: 10.1111/apm.13225 |
10 |
OSADCHIY V, MARTIN C R, MAYER E A. The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications[J]. Clin Gastroenterol Hepatol, 2019, 17(2):322-332. doi:10.1016/j.cgh.2018.10.002
doi: 10.1016/j.cgh.2018.10.002 |
11 |
YIN Y, GUO Q, ZHOU X, et al. Role of brain-gut-muscle axis in human health and energy homeostasis[J]. Front Nutr, 2022, 9:947033. doi:10.3389/fnut.2022.947033
doi: 10.3389/fnut.2022.947033 |
12 |
FLANNONE L F, GOMEZ-EGUILAZ M, DE CARO C. Gut microbiota manipulation as an epilepsy treatment[J]. Neurobiol Dis, 2022,174:105897. doi:10.1016/j.nbd.2022.105897
doi: 10.1016/j.nbd.2022.105897 |
13 |
LYU Y, YANG H, CHEN L. Metabolic regulation on the immune environment of glioma through gut microbiota[J]. Semin Cancer Biol, 2022, 86(Pt 2):990-997. doi:10.1016/j.semcancer.2021.05.005
doi: 10.1016/j.semcancer.2021.05.005 |
14 | 刘树昕,吴爱娟,甄妮,等. 广谱抑菌乳酸菌的筛选及其细菌素相关基因分析[J]. 食品科学, 2020,41(6):101-107. |
15 |
DONO A, NICKLES J, RODRIGUEZ-ARMENDARIZ A G, et al. Glioma and the gut-brain axis: opportunities and future perspectives[J]. Neurooncol Adv, 2022,4(1):vdac054. doi:10.1093/noajnl/vdac054
doi: 10.1093/noajnl/vdac054 |
16 |
HOU X, DU H, DENG Y, et al. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma[J]. J Transl Med, 2023,21(1):198. doi:10.1186/s12967-023-04042-5
doi: 10.1186/s12967-023-04042-5 |
17 |
PATRIZZ A, DONO A, ZOROFCHIAN S, et al. Glioma and temozolomide induced alterations in gut microbiome[J]. Sci Rep, 2020,10(1):21002. doi:10.1038/s41598-020-77919-w
doi: 10.1038/s41598-020-77919-w |
18 |
D'AlESSANDRO G, LAURO C, QUAGLIO D, et al. Neuro-Signals from Gut Microbiota: Perspectives for Brain Glioma[J]. Cancers (Basel), 2021,13(11):2810. doi:10.3390/cancers13112810
doi: 10.3390/cancers13112810 |
19 |
DONO A, NICKLES J, RODRIGUEZ-ARMENDARIZ A G, et al. Glioma and the gut-brain axis: opportunities and future perspectives[J]. Neurooncol Adv, 2022,4(1):vdac054. doi:10.1093/noajnl/vdac054
doi: 10.1093/noajnl/vdac054 |
20 |
FAN Y, SU Q, CHEN J, et al. Gut Microbiome Alterations Affect Glioma Development and Foxp3 Expression in Tumor Microenvironment in Mice[J]. Front Onco, 2022,12:836953. doi:10.3389/fonc.2022.836953
doi: 10.3389/fonc.2022.836953 |
21 | YOSHIKAWA S, TANIGUCHIi K, SAWAMURA H, et al. Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma[J]. Explor Target Antitumor Ther, 2022,3(6):817-827. |
22 |
GOPALAKRISHNAN V, HELMINK B A, SPENCER C N, et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy[J]. Cancer Cell, 2018,33(4):570-580. doi:10.1016/j.ccell.2018.03.015
doi: 10.1016/j.ccell.2018.03.015 |
23 |
ZHU J, SU J. Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy[J]. Indian J Microbiol, 2022,62(1):23-31. doi:10.1007/s12088-021-00962-2
doi: 10.1007/s12088-021-00962-2 |
24 |
ZHANG X, ZHAO L, ZHANG H, et al. The immunosuppressive microenvironment and immunotherapy in human glioblastoma[J]. Front Immunol, 2022,13:1003651. doi:10.3389/fimmu.2022.1003651
doi: 10.3389/fimmu.2022.1003651 |
25 |
LIANG J, LI T, ZHAO J, et al. Current understanding of the human microbiome in glioma[J]. Front Oncol, 2022,12:781741. doi:10.3389/fonc.2022.781741
doi: 10.3389/fonc.2022.781741 |
26 |
QIU Q, LIN Y, MA Y, et al. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy[J]. Front Immunol, 2021,11:612202. doi:10.3389/fimmu.2020.612202
doi: 10.3389/fimmu.2020.612202 |
27 | 何宝坤. 基于肠道菌群发现用于治疗Treg缺失免疫缺陷病的新药[J]. 中国药理学与毒理学杂志, 2019,33(9):750. |
28 |
KAZMIERCZAK-SIEDLECKA K, MARANO L, MEROLA E, et al. Sodium butyrate in both prevention and supportive treatment of colorectal cancer[J]. Front Cell Infect Microbiol, 2022,12:1023806. doi:10.3389/fcimb.2022.1023806
doi: 10.3389/fcimb.2022.1023806 |
29 |
Al-QADAMI G H, SECOMBE K R, SUBRAMANIAM C B, et al. Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities[J]. Microorganisms, 2022,10(10):2048. doi:10.3390/microorganisms10102048
doi: 10.3390/microorganisms10102048 |
30 |
MA X, MA L, WANG Z, et al. Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis-A Pilot Study[J]. Front Neurol, 2020, 11:585977. doi:10.3389/fneur.2020.585977
doi: 10.3389/fneur.2020.585977 |
31 |
XIONG R G, ZHOU D D, WU S X, et al. Health Benefits and Side Effects of Short-Chain Fatty Acids[J]. Foods, 2022,11(18):2863. doi:10.3390/foods11182863
doi: 10.3390/foods11182863 |
32 |
WANG L, LI S, FAN H, et al. Bifidobacterium lactis combined with Lactobacillus plantarum inhibit glioma growth in mice through modulating PI3K/AKT pathway and gut microbiota[J]. Front Microbiol, 2022,13:986837. doi:10.3389/fmicb.2022.986837
doi: 10.3389/fmicb.2022.986837 |
33 |
LI X C, WU B S, JIANG Y, et al. Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma[J]. Drug Des Devel Ther, 2021,15:1641-1652. doi:10.2147/dddt.s298261
doi: 10.2147/dddt.s298261 |
34 |
JIANG H, ZENG W, ZHANG X, et al. The role of gut microbiota in patients with benign and malignant brain tumors: a pilot study[J]. Bioengineered, 2022,13(3):7847-7859. doi:10.1080/21655979.2022.2049959
doi: 10.1080/21655979.2022.2049959 |
35 |
ŁANIEWSKI P, ILHAN Z E, HERBST-KRALOVETZ M M. The microbiome and gynaecological cancer development, prevention and therapy[J]. Nat Rev Urol, 2020,17(4):232-250. doi:10.1038/s41585-020-0286-z
doi: 10.1038/s41585-020-0286-z |
36 |
SI W, LIANG H, BUGNO J, et al. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade[J]. Gu, 2022,71(3):521-533. doi:10.1136/gutjnl-2020-323426
doi: 10.1136/gutjnl-2020-323426 |
[1] | Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267. |
[2] | Nan LI,Xue ZHAO, A′nali,Heran LIANG,Na. GE. Research progress on the role of bile acids in alcoholic liver disease [J]. The Journal of Practical Medicine, 2024, 40(15): 2187-2193. |
[3] | Hua JIANG,Limin ZHANG,Dan WANG,Ping HAN,Yuehong SUN,Yuwen LI,Chenxi ZHANG,Wencan JIANG,Xiao LI,Hui. ZHAO. Clinical value of joint detection of cerebrospinal fluid and blood routine indicators in differentiating between multiple gliomas and primary central nervous system lymphoma [J]. The Journal of Practical Medicine, 2024, 40(13): 1864-1868. |
[4] | Yanwei HUANG,Kaitai ZENG,Ziqi WEN,Yan LI,Rongping. CHEN. Markers of gut flora in Parkinson′s disease: A literature review [J]. The Journal of Practical Medicine, 2024, 40(11): 1473-1478. |
[5] | Xinwen BI,Yuanjie CUI,Qiuxian LU,Jia CUI,Fan BU,Fang HE,Hua YANG,Ming. LI. Immunomodulatory effects of intestinal flora on glucose and lipid metabolism disorders in high⁃fat diet induced obese mice [J]. The Journal of Practical Medicine, 2024, 40(11): 1505-1512. |
[6] | Qi ZHANG,Jia HU,Hui LI,Jin WANG,Zhongde LI,Zhiyuan. HU. Correlations of miR⁃203a⁃3p and PHOX2B expression in glioma tissues with clinical features and prognosis [J]. The Journal of Practical Medicine, 2024, 40(10): 1382-1388. |
[7] |
LI Mengxin, HUI Lei, JI Qiankun, WANG Shuren, LI Haiming, JIN Baozhe..
ANXA1 is upregulated in glioblastoma and promoting malignant progression of glioblastoma [J]. The Journal of Practical Medicine, 2023, 39(8): 928-935. |
[8] | Xianda CHEN, Nan MA, Shengjie GUO, Zhenhua LIU, Kai. YAO. Efficacy and safety of anlotinib monotherapy and combinated therapy in the treatment of advanced pheochromocytoma/paraganglioma [J]. The Journal of Practical Medicine, 2023, 39(23): 3106-3110. |
[9] | Yuanjian LIAO,Jingjing YAO,Mingshun ZUO,Hongchuan CHEN,Te XU,Neng. ZHANG. Progress in genetic research on metastatic pheochromocytoma and paraganglioma [J]. The Journal of Practical Medicine, 2023, 39(23): 3137-3142. |
[10] | Ming LI,Wei SU,Shiheng. MA. Analyze of the value of bifidum in the treatment of sepsis caused by pulmonary infection based on intestinal immunity [J]. The Journal of Practical Medicine, 2023, 39(18): 2384-2388. |
[11] | Hua PAN,Minshang ZHANG,Xu WANG,Dandan. JIANG. Effect of Qi Chang Xue Xing Tang retention enema combined with heat sensitive moxibustion on gastrointestinal function and immune function of patients after radical gastrectomy [J]. The Journal of Practical Medicine, 2023, 39(16): 2130-2135. |
[12] | GUO Yansong, LI Sirou, LI Lin, ZENG Zhaomu, BAI Zetong, WEN Xichao, ZHENG Kebin. . Research progress of m6A modification in glioma [J]. The Journal of Practical Medicine, 2023, 39(13): 1724-1728. |
[13] | MA Jun, XIANG Mei. . Effects of lidocaine on the malignant biological behavior of glioma cells through SHH/GLI signaling pathway [J]. The Journal of Practical Medicine, 2023, 39(11): 1403-1408. |
[14] | LEI Yu, HU Yaxin, YU Lei, CHENG Mingliang, CHENG Zhuo, CONG Shuo, PU Qian, ZHENG Lin. . Effect of intrahepatic cholestasis on bile acid spectrum and intestinal flora in ileocecum of mice [J]. The Journal of Practical Medicine, 2023, 39(10): 1232-1236. |
[15] |
ZHANG Chenchen, YU Meiling, TAN Weiguo, WU Zhuhua, WEI Wenjing. .
Effects of Mycobacterium tuberculosis infection and conventional anti⁃tuberculosis chemotherapy on gut mi⁃ crobiota [J]. The Journal of Practical Medicine, 2022, 38(6): 678-684. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||